Dihydroergotamine mesilate - POZEN

Drug Profile

Dihydroergotamine mesilate - POZEN

Alternative Names: Dihydroergotamine mesylate injection - POZEN; MT-300

Latest Information Update: 19 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator POZEN
  • Class Antimigraines; Ergotamines; Mesylates; Small molecules
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 02 Mar 2005 Xcel Pharmaceuticals has been acquired by, and merged into, Valeant Pharmaceuticals International
  • 04 Nov 2004 Preregistration for Migraine in USA (Injection)
  • 08 Sep 2003 Xcel Pharmaceuticals has licensed the commercialisation rights for MT 300 in the United States
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top